Our activity

We are a dedicated team focused on Research and Development of innovative Antibody-Drug Conjugates (ADCs) . ADCs work by utilizing the specificity of antibodies to target specific antigens expressed on the surface of cancer cells. Once the ADC binds to the antigen, it is internalized, leading to the release of the cytotoxic agent inside the cancer cell, effectively killing it. ADCs represent a groundbreaking advancement in targeted cancer therapy. 

The mechanism of action

By linking potent cytotoxic drugs to monoclonal antibodies, ADCs enable precise delivery of chemotherapy directly to cancer cells, minimizing damage to healthy tissues. This innovative approach enhances the efficacy of cancer treatments while potentially reducing side effects.

The development process

The development of ADCs involves several stages:

Antibody Selection: Identifying antibodies that specifically target cancer cell antigens.

Linker Technology: Developing stable or unstable linkers that connect the drug to the antibody while ensuring safe release once inside the cell. Some ADCs do not need linkers (linker-less ADCs). 

Cytotoxic Agent Development: Selecting potent chemotherapy drugs that can effectively destroy cancer cells.

Current Landscape and Future Directions

With several ADCs already approved, ongoing research focuses on improving potency, targeting new cancer types, and enhancing patient responses. Future advancements aim to refine linker technologies and expand the therapeutic arsenal, promising a brighter future for cancer patients